Title
Category
Credits
Event date
Cost
  • Alzheimer Disease
  • Antipsychotics
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • Parkinson Disease
  • Psychotic Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Antipsychotics can be used in the short-term to manage dementia-related psychosis, but serious adverse effects can outweigh benefits. Novel antipsychotics or other agents may offer superior efficacy and safety. Explore the evidence in this CME activity.
  • Psychopharmacology
  • Side Effects
  • Depression
  • Bipolar Disorder
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Join Dr Goldberg as he reviews factors that impact the diagnosis of bipolar disorder and current treatments for bipolar depression in adults.
  • Psychopharmacology
  • Side Effects
  • Child and Adolescent Psychiatry
  • Depression
  • Bipolar Disorder
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What are the evidence-based pharmacologic treatment approaches for pediatric patients with bipolar depression?
  • Patient/Physician Communication
  • Mood Disorders
  • Child and Adolescent Psychiatry
  • Depression
  • Bipolar Disorder
  • Antipsychotics
  • Antidepressants
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Findling and Goldberg offer expertise on the diagnosis and treatment of bipolar disorder in patients of all ages.
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • Neuroimaging
  • Patient/Physician Communication
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
  • Child and Adolescent Psychiatry
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Long COVID symptoms are both physical and mental in nature among children and adolescents and have the potential to affect long-term functioning and increase the overall burden on health care delivery.
  • Mood Disorders
  • Depression
  • Electroconvulsive Therapy
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this chart review, LGBTQ people with treatment-resistant mood disorders had clinical features linked to worse outcomes, but their improvement with ECT was similar to that seen in non-LGBTQ patients.
  • Bipolar Disorder
  • Schizophrenia/ Schizoaffective Disorders
  • Smoking
  • Substance Use Disorders
  • Suicide
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Predicting suicide is difficult, as suicidal behavior is not linked solely to any single behavior or psychiatric diagnosis. This study compared risk of suicidal behavior among a transdiagnostic sample of Veterans with varying disorders and behaviors.
  • Myasthenia Gravis
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patients with generalized myasthenia gravis (gMG) receive multiple immunosuppressive therapies, but with incomplete suppression of IgG autoantibodies. Read this rapid update in gMG to learn about novel therapies that can more effectively suppress IgG autoantibodies through a novel mechanism of action to help your patients achieve better clinical outcomes.
  • Primary Care
  • Patient/Physician Communication
  • Neuroimaging
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.

Pages